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1. Introduction 
The development of encephalitis presents a dilemma to the clinician as during the early 
stages, when treatment would be most effective, the symptoms can be nonspecific with a 
broad differential.  Imaging tests (e.g. magnetic resonance imaging and computed axial 
tomography scan), blood and urine tests as well as lumbar puncture are used to isolate and 
identify viruses, and together with careful and continuous neurological assessment provide 
data that may be suggestive of viral encephalitis. In the case of post-infectious or 
autoimmune encephalitis, a more intense investigation is needed to generate an accurate 
diagnosis. In addition to imaging tests and electroencephalography, blood and 
cerebrospinal fluid (CSF) need to be analyzed for evidence of inflammation and the presence 
of antibodies against cellular antigens. In recent years clinicians and investigators have 
pursued biomarkers that can aid in the diagnosis as well as prognosis and monitoring of 
patients with encephalitis. These biomarkers are increasingly important in the recognition 
and treatment of inflammatory and autoimmune central nervous system (CNS) disorders. 
This chapter will review the current literature of emerging biomarkers in the different types 
of encephalitis. 
2. Infectious encephalitis 
2.1 HIV encephalitis 
HIV encephalitis (HIVE) is characterized by the presence of microglial nodules, 
multinucleated giants cells, glial activation and neuronal loss (Budka 1991). About 25% of 
immunosuppressed patients infected with HIV develop neurological deficits ranging from 
cognitive impairments, motor abnormalities, behavioral symptoms to HIV-associated 
dementia (HAD) (Dore et al 1999; Nath & Sacktor 2006). In HIVE macrophages/microglia 
are productively infected with HIV and are hypothesized to play a pivotal role in the 
neurodegenerative process leading to HAD (Ellis et al 2007; Navia et al 1986). The need to 
diagnose the pathogenic process of HIVE and HAD led to the pursuit for plasma and CSF 
biomarkers that might provide insight into pathogenesis and also facilitate the diagnosis 
and disease staging in addition to clinical signs and symptoms. 
Historically, HIV-1 RNA load was measured in the brain and CSF of HIV-infected patients 
to verify whether it could be a marker of HIV-induced neuropathology (Achim et al 1994; 
Cinque et al 1998). Cinque et al. examined HIV-infected patients with neurological 
symptoms for the presence of HIV-1 p24 antigen by immunohistochemistry as well as CSF 
HIV-1 RNA by quantitative polymerase chain reaction (PCR). Their results showed that CSF 
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HIV-1 RNA copy numbers were significantly higher in patients with HIV encephalitis than 
in patients without encephalitis. From this study they concluded that CSF HIV-1 RNA levels 
were associated with HIVE and the associated neuropathology (Cinque et al 1998). 
Although there were studies that did not show significant difference in CSF levels of HIV-1 
RNA between patients with or without HIVE (Bossi et al 1998) many studies in non-human 
primates infected with simian immunodeficiency virus (SIV) confirmed a correlation 
between SIV viral load and encephalitis (Bissel et al 2008; Bonneh-Barkay et al 2008; Zink et 
al 1999; Zink et al 2005). 
Because macrophages are the predominant immune cell and the predominant infected cell 
in the brains of patients with HIVE, it was assumed that immune activation-associated 
factors in the CSF could serve as a surrogate biomarker for the disease. One of those factors 
is neopterin, an intermediate of pteridine metabolism, that is produced by activated 
macrophages in response to cytokines (Anderson et al 2002; Williams & Hickey 2002) that 
was also found to predict systemic disease progression (Fuchs et al 1989b) . Several studies 
showed that neopterin was elevated in the CSF of HIV-infected patients, particularly 
patients with HAD (Brew et al 1990; Fuchs et al 1989a; Sonnerborg et al 1989). However 
Wiley et al. did not find a strong correlation between CSF neopterin and severity of 
encephalitis in autopsied patients with HIVE  (Wiley et al 1992). A recent study by Hagberg 
at al. showed that in untreated HIV-infected patients CSF neopterin concentrations were 
almost always elevated and increased progressively as immunosuppression worsens and 
blood CD4 cell counts fell. Patients with HAD exhibit particularly high CSF neopterin 
concentrations, above those of patients without neurological disease suggesting that this 
might be a useful CNS disease marker (Hagberg et al 2010). 
Additional factors that suggest immune activation are of course cytokines and chemokines. 
Previous studies showed that some HIV patients exhibited elevated CSF levels of 
interleukin-1┚ (IL-1┚) and interleukin-6 (IL-6) but no tumor necrosis factor-┙ (TNF) or 
interleukin-2 (IL-2) were detected (Gallo et al 1989). In contrast other studies reported high 
levels of CSF TNF in HIV-1 sero-positive patients who had neurologic involvement 
(Sharief et al 1992). The profile of cytokines may differ according to the level of 
macrophage/microglia infection or activation or the presence of opportunistic infections. 
Previous studies have also tried to establish correlations between CSF chemokines and CSF 
HIV viral load. Increased CSF levels of chemokines like CCL2 (also known as MCP-1), were 
reported in patients with HIVE and HAD (Kelder et al 1998). Moreover, recent reports 
showed a possible association between CSF CCL2 levels and the development of HAD, 
suggesting that this chemokine could be used as a biomarker of disease progression (Cinque 
et al 2005; Sevigny et al 2004; Sevigny et al 2007). Furthermore Almeida et al. obtained 
similar results and also suggested that CCL2 expression was associated with leukocyte 
transmigration into the CNS (Monteiro de Almeida et al 2006; Monteiro de Almeida et al 
2005). In addition, CXCL10 was found to be positively correlated with CSF HIV viral load 
(Christo et al 2009; Gisolf et al 2000) and CSF pleocytosis (Cinque et al 2005; Kolb et al 1999) 
suggesting that this chemokine may contribute to HAD pathogenesis (Christo et al 2005). 
Activation of the plasminogen system has been reported in different neurological disorders 
such as stroke and other forms of acute brain injury (Bonneh-Barkay & Wiley 2008). 
Expression of the urokinase plasminogen activator (uPA) and its receptor (uPAR) was also 
found in HIV-1-associated CNS disease (Sidenius et al 2004). CSF soluble uPAR levels were 
significantly higher in HIV-infected patients than in HIV-negative controls. Moreover CSF 
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soluble uPAR levels correlated with CSF HIV-1 RNA, but not with plasma soluble uPAR 
concentrations. In addition, highly active antiretroviral therapy (HAART) was associated 
with a significant decrease of CSF soluble uPAR in parallel to reduction in viral load 
(Cinque et al 2004).  
A recently identified biomarker for HIVE is YKL-40 (chitinase 3-like protein 1, HC-gp39). 
YKL-40 is up-regulated in inflammatory conditions (e.g. Crohn’s disease and rheumatoid 
arthritis) as well as in cancers (e.g. melanoma, glioblastoma, and myeloid leukemia) 
(Kirkpatrick et al 1997; Rehli et al 2003). In addition it was found to be induced in astrocytes 
in acute and chronic neurological conditions (Bonneh-Barkay et al 2010a).  
Unbiased proteomics approach was used to identify proteins that are differentially 
expressed in the CSF of SIV-infected macaques that develop encephalitis. Among the 
proteins that showed differential up-regulation was YKL-40. Longitudinal analysis of CSF 
from SIV-infected pigtailed macaques showed an increase in YKL-40 concentration 2 to 8 
weeks before death from encephalitis. This increase in YKL-40 correlated with an increase in 
CSF viral load (Bonneh-Barkay et al 2008). Similar results were obtained in CSF from HIV 
patients. YKL-40 was higher in patients with HIV viral load higher than 10,000 copies/ml 
(Figure 1A) and there was a significant elevation in CSF YKL-40 in HIV patients with HIVE  
 
 
Fig. 1. (A) CSF from HIV-infected patients categorized on the basis of CSF HIV RNA copies 
(Low viral load=<10,000 HIV copies; High viral load=>10,000 HIV copies) was analyzed for 
YKL-40. (B) CSF YKL-40 correlation with HIVE pathology. (C) YKL-40 localized in 
astrocytes and occasional CNS activated macrophage/microglia in HIVE. Triple-label 
immunofluorescence for YKL-40 (green) and CD68 (blue) or glial fibrillary acidic protein 
(GFAP) (red). Co-localization of YKL-40 and astrocytes appears as yellow and co-
localization of YKL-40 and CD68 positive macrophages is evident as aqua signal 
(arrowheads); scale bar=50m (Bonneh-Barkay et al 2008). 
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versus patients without encephalitis (Figure 1B). Previous studies have shown that high 
viral load in the CSF correlates with the severity of SIV encephalitis (SIVE) (Bissel et al 2006; 
Zink et al 1999) and HIVE (Cinque et al 1998; Wiley et al 1998). The correlation between 
YKL-40 levels and CSF viral load in SIVE and HIVE further support its potential use as a 
biomarker of HIVE. Immunohistochemistry showed that YKL-40 is expressed in astrocytes 
in the vicinity of microglial nodules in HIVE (Figure 1C).  
It seems that YKL-40 can serve as a biomarker for Neuroinflammation in general as our 
recent study also showed that CSF YKL-40 levels are elevated in patients with severe 
traumatic brain injury (TBI), and that they correspond to levels of inflammatory cytokines 
(Bonneh-Barkay et al 2010b). In addition our previous study showed more pronounced 
YKL-40 expression in patients with acute infarcts and diminished expression in subacute or 
older infarcts (Bonneh-Barkay et al 2010a). In that previous study, combined ISH and GFAP 
staining showed induced YKL-40 expression in astrocytes that was restricted to the 
penumbra of the infarct. While the precise biological functions of YKL- 40 are speculative, 
its expression is related to inflammation in a variety of disease states. Further work is 
required to further evaluate the utility of YKL-40 as a biomarker and its role in 
Neuroinflammation. 
2.2 Herpes simplex encephalitis 
Herpes simplex encephalitis (HSE) is an acute or subacute illness, causing both general and 
focal signs of cerebral dysfunction induced by Herpes simplex virus type 1 (HSV–1) 
(Kennard & Swash 1981; Koskiniemi et al 1996; Miller & Ross 1968; Sivertsen & Christensen 
1996; Whitley et al 1989). HSV invades the CNS and is capable of replicating in neurons and 
glial cells which produce acute focal, necrotizing encephalitis localized in the temporal and 
subfrontal regions of the brain, often with a progressive course (Booss & Kim 1984). Early 
treatment with acyclovir is important to decrease mortality and limit CNS injury in HSE 
(Skoldenberg 1991). In addition corticosteroids may be given as therapy during the acute 
phase of HSE in order to reduce inflammation and edema in the CNS (Skoldenberg et al 
1984). Despite adequate treatment almost all surviving patients suffer from neurological 
sequelae. The most common long-term symptoms after HSE are memory impairment, 
personality and behavioral abnormalities and epilepsy (McGrath et al 1997). 
Confirmation of the diagnosis depends on the identification of HSV in the CSF by means of 
PCR although in some cases the PCR can be negative. In these cases detection of intrathecal 
synthesis of specific immunoglobulins could be useful (Denes et al 2010; Felgenhauer et al 
1982; Felgenhauer & Reiber 1992; Reiber & Lange 1991). Widespread viral replication has 
not generally been found beyond the acute stage of HSE. Histopathologic studies of autopsy 
specimens showed that HSV antigen was detected in the brains of 21 out of 29 who died 
within 3 weeks after the onset of neurologic disease but not in the 8 who died thereafter 
(Booss & Kim 1984). HSV DNA seems to be cleared from the CSF in about the same period 
(Aurelius et al 1991), but PCR has shown HSV DNA at autopsy in a few cases of late-stage 
HSE. Despite lack of firm evidence, it seems that a low-grade continuous or recurrent viral 
replication may occur in certain foci resulting in continued antigen stimulation. Thus in 
general PCR is more useful in diagnosing acute HSE. 
In HSE there is evidence of a vigorous intrathecal immune response during the acute phase, 
as shown by increased levels of 2-microglobulin and neopterin in CSF, followed by a 
chronic phase of low-grade intrathecal inflammation (Aurelius et al 1993).  In addition the 
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levels of a variety of CSF cytokines and their receptors are elevated like IL-6, IFN, soluble 
IL-2 receptor (sIL-2R) and soluble CD8 (Asaoka et al 2004; Aurelius et al 1994; Ichiyama et al 
2008; Linde et al 1992; Rosler et al 1998). IFN and IL-6 levels increased during the first week 
of HSE while TNF, IL-2, and soluble CD8 became elevated at 2–6 weeks (Aurelius et al 
1994). A more recent study tried to assess whether there is a correlation between cytokines 
levels and outcomes. Kamei et al. showed that initial IFN and maximum IL-6 levels in 
patients with a poor outcome were higher than those with a good outcome and thus could 
serve as prognostic biomarkers in HSE (Kamei et al 2009). 
Patients with viral CNS infections have previously been studied with regard to neuronal 
and astroglial markers in CSF (Rosengren et al 1994; Sindic et al 1985). The concentrations 
and kinetics of these markers in HSE imply that they may be used as brain damage markers 
to follow individual patients longitudinally or to evaluate therapeutics. Studahl et al. 
followed neuronal and astroglial marker proteins for up to 6 months in patients with HSE 
and found markedly higher CSF levels of neuron specific enolase (NSE), neurofilament 
protein, GFAP and S100 in the acute stage of HSE that was decreased within 45 days after 
acute infection (Studahl et al 2000). Although high levels of these markers were associated 
with neurological damage in other acute CNS damaging disorders, such as cerebral 
infarction (S100 and GFAP) (Aurell et al 1991), neonatal asphyxia (Blennow et al 1995), and 
after cardiac arrest (NSE) (Karkela et al 1993) Studahl et al. were not able to evaluate the 
prognostic use of these CSF markers in HSE. It seems that other factors (e.g. duration of 
disease before start of treatment, age, localization of the infected area and size of 
hemorrhagic necrosis) can influence the clinical outcome. Bigger cohorts may be needed to 
determine whether concentrations are correlated with clinical outcome (Studahl et al 2000). 
Additional biomarker that might indicate the severity and progression of cerebral injury in 
HSE is soluble Fas (sFas) which is involved in apoptosis through the Fas/Fas Ligand 
pathway (Sabri et al 2006). Elevated levels of sFas have been reported in a variety of 
neurological diseases like HIVE, TBI and multiple sclerosis (De Milito et al 2000; Felderhoff-
Mueser et al 2001; Lenzlinger et al 2002; Mogi et al 1996; Sabri et al 2001; Towfighi et al 2004; 
Zipp et al 1998). Sabri et al. found high levels of sFas in CSF samples collected after 
neurological onset in 84% of HSE patients. In addition they observed that HSE patients with 
severe neurological sequels had an increase in changes of CSF sFas as compared to patients 
with mild or moderate neurological outcome.  
In summary, markers of immune activation (e.g. IL-6, IFN, neopterin and 2-
microglobulin) are found early during the course of HSE and high levels are found to 
correlate with severe clinical outcome as well as with mortality (Aurelius et al 1993). 
Additionally there are markers that are indicative of persistent immune activation like 
soluble IL-2R and CD68 (Aurelius et al 1994).  
2.3 Influenza-associated encephalopathy 
Influenza-associated encephalopathy (IAE) is a CNS complication with high mortality and 
neurological sequelae with estimated mortality rate of 27% to 44% (Morishima et al 2002). 
The clinical symptoms of IAE include symptoms of both flu and CNS dysfunction. CNS 
neurological manifestations including seizure, altered or loss of consciousness, decreased 
cognitive performance, motor paralysis or sensory loss, abnormal or delirious behavior, and 
change in mental status. The neurological complications usually appear within several days 
of the first symptoms of flu (Wang et al 2010). 
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The influenza-virus usually can not be detected in the CNS of IAE patients and thus the 
pathophysiology of IAE remains unclear. The early studies reported that thrombocytopenia 
and severely elevated serum aspartate aminotransaminase levels were associated with a 
poor prognosis (Morishima et al 2002). High concentration levels of various cytokine such as 
IL-6 and TNF have been reported (Aiba et al 2001; Hosoya et al 2005; Ichiyama et al 1998; 
Togashi et al 2004). Ichiyama et al. reported significantly higher levels of serum and CSF IL-
6 in the IAE group with a poor prognosis relative to the group without sequelae. In addition 
serum levels of soluble TNFR1 and IL-10 levels were higher (Hasegawa et al 2011; Ichiyama 
et al 2004). Hosoya et al. reported significantly elevated levels of TNF and cytochrome c 
concentrations in patients with poor prognosis as compared to good outcome (Hosoya et al 
2005). The authors suggested that apoptosis of the CNS parenchyma contributes to the 
cerebral atrophy observed in patients with sequelae.  
Recently, a new test for the evaluation of oxidative status, the Diacron-Reactive Oxygen 
Metabolites (d-ROM) test, has become available (Cesarone et al 1999). Yamanaka et al. 
assessed the prognostic value of serum and CSF d-ROM levels of patients with IAE in the 
initial stage (Yamanaka et al 2008; Yamanaka et al 2006). CSF d-ROM levels showed that the 
oxidative trend status corresponds to the therapeutic response and thus oxidative stress may 
be related to the pathogenesis of IAE. Similar results by Kawashima et al. showed high 
concentrations of NOx levels in the serum and CSF of the patients with IAE during the 
initial stage (Kawashima et al 2002; Kawashima et al 2003).  
Another approach to discovering specific biomarkers of patients with IAE was to analyze all 
metabolites in CSF by using metabolome analysis. Two metabolites (molecular weights:  
246.0092 and 204.0611) were significantly higher than those in other diseases including 
influenza without convulsion. These results indicate that the metabolites detected in CSF 
could serve as primary markers for the diagnosis of IAE (Kawashima et al 2006). 
2.4 West Nile Virus encephalitis  
West Nile virus (WNV) is a mosquito-borne, neurotropic , single-stranded sense RNA 
flavivirus (Brehin et al 2008). The classical symptoms of WNV infection range from fever 
(Hayes & Gubler 2006; Leis & Stokic 2005; Leis et al 2002; Leis et al 2003; Nash et al 2001; 
Sejvar et al 2003; Tilley et al 2007) to CNS disease of severe meningoencephalitis (Petersen & 
Marfin 2002). Clinical symptoms of CNS disease include persistent weakness, flaccid 
paralysis, myelitis, ataxia, seizures, or change in mental status. Neurological signs in WNV 
infection have been reported in about 42% of the cases. 
One of the main diagnostic criteria for neurologic involvement in WNV infection is the 
presence of WNV IgM in CSF though it can be detected in the CSF for more than 6 months 
(Kapoor et al 2004). Therefore a more specific marker is necessary in order to distinguish 
WNV from other infections with neurological symptoms. Nixon et al. evaluated CSF WNV 
IgA as a marker of WNV neuroinvasive infection but found that it had equivalent value to 
IgM (Nixon & Prince 2006).  
In addition to specific antibodies, protein biomarkers are an attractive tool for assessing 
neuronal death and glial pathology. Petzold et al. showed a significant elevation of those 
CSF proteins like GFAP, S100B, and neurofilament-SMI35 in patients suffering from WNV 
CNS disease (Petzold et al 2010). However, CSF GFAP and S100B were also increased in all 
of patients with WNV fever only thus decreasing their usefulness as a biomarker for CNS 
disease. Interestingly, in patients that died from the disease high CSF S100B levels were 
related to a shorter time to death.  
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In summary, most of the studies aiming to discover biomarkers of viral encephalitides were 
targeted towards studying known pathways believed to be involved in immune activation 
or cell damage. These studies, however, have achieved limited success. Over the last few 
years, unbiased proteomic techniques have been utilized to discover novel biomarkers in 
different diseases without the a priori selection of specific proteins (Romeo et al 2005). In 
recent years there are more and more studies using those techniques to discover biomarkers 
in neurological conditions and neurodegenerative diseases (e.g. multiple sclerosis and 
Alzheimer’s disease) (Craig-Schapiro et al 2010; Ottervald et al 2010; Perrin et al 2011). 
Unbiased proteomics profiling is very complex and requires a multi-discipline approach 
from sample preparation and protein identification to data processing and validation. These 
analyses most likely will result a combination of candidate biomarkers that will need to be 
tested in larger cohorts.  
3. Autoimmune encephalitis 
Autoimmune encephalitis encompasses a variety of disorders resulting from an immune 
reaction against antigens expressed in neurons. As a result there is rapidly progressive 
cognitive decline and behavioral abnormalities. The antibodies against those antigens are 
important markers for these disorders (Vitaliani et al 2008). 
3.1 Limbic encephalitis 
Paraneoplastic neurologic disorders are immunologic complications induced by 
malignancies that express proteins that are usually restricted to the CNS (Vernino et al 
2007). They are characterized by memory impairment, temporal lobe seizures and 
psychiatric symptoms. The most common tumors associated with paraneoplastic 
neurological disorders are small-cell lung carcinoma (SCLC), testicular cancer, thymoma 
and breast cancer (Ahern et al 1994; Gultekin et al 2000; Vernino & Lennon 2004).  
A variety of autoantibody markers are associated with limbic encephalitis like anti-Hu and 
anti-CV2/CRMP5 (Gultekin et al 2000; Voltz 2002). In recent years different subtypes of this 
disorder have been discovered as well as new antigens. Anti-N-Methyl-D-aspartate receptor 
(NMDAR) encephalitis was identified as a subtype of limbic encephalitis. This disease 
usually starts with an episode of fever, headache, or malaise, followed by mood and 
behavioral changes, psychiatric symptoms and decline of consciousness that could 
deteriorate to death. It usually affects young women and is associated with ovarian 
teratoma. These patients demonstrate serum and CSF presence of antibodies against NMDA 
receptor subunit 1 (NR1) and NMDA receptor subunit 2 (NR2) (Iizuka et al 2008). 
Additional subtype of limbic encephalitis is characterized by antibodies against voltage 
gated potassium channels (VGKC) (Buckley et al 2001; Thieben et al 2004; Vincent et al 
2004). VGKC limbic encephalitis is mostly non-paraneoplastic, although VGKC antibodies 
have been found in a small number of patients with tumors (Pozo-Rosich et al 2003). Jarius 
et al. showed that even patients without CSF pathological findings or inflammatory changes 
can be positive for VGKC antibodies (Jarius et al 2008).  
Non-herpetic acute limbic encephalitis (NHALE) has been identified as a new subgroup of 
limbic encephalitis with a clinical presentation which is similar to HSE (Asaoka et al 2004; 
Ichiyama et al 2009; Kusuhara et al 1994; Shoji et al 2004). Autopsy cases showed neuronal 
loss and severe gliosis with inflammatory cell infiltrations in the hippocampus and 
amygdala. Examination of the CSF revealed occasional mild pleocytosis, and increased IL-6 
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levels (Ichiyama et al 2008; Shoji 2010). Recent reports associate the disease with the 
presence of anti-glutamate receptor epsilon 2 antibodies (Shoji 2010). Takahashi et al. 
reported the presence of those antibodies in the serum and CSF of patients in acute and 
chronic stages (Takahashi et al 2010). 
3.2 Hashimoto’s encephalopathy 
Hashimoto's encephalopathy (HE) is a rare autoimmune disease affecting mostly women 
that is associated with elevated titers of antithyroid antibodies in serum and CSF (Brain et al 
1966; Chong et al 2003). HE is characterized by various neuropsychological symptoms, 
including personality changes, cognition deterioration, seizures, myoclonus and loss 
consciousness (Ghika-Schmid et al 1996; Henchey et al 1995; Kothbauer-Margreiter et al 
1996; Mijajlovic et al 2010; Peschen-Rosin et al 1999; Shaw et al 1991). HE patients show high 
CSF protein levels (oligoclonal bands or an increased total protein concentration) without 
pleocytosis and high titer of antithyroid antibodies (Archambeaud et al 2001; Ferracci & 
Carnevale 2006; Hartmann et al 2000; Shaw et al 1991). The etiology of the disease is not 
entirely clear but there are some reports claiming an inflammatory response to antineuronal 
antibodies (Oide et al 2004; Takahashi et al 1994). 
3.3 Rasmussen’s encephalitis 
Rasmussen’s encephalitis is an acquired progressive inflammatory encephalopathy 
characterized by seizures and cognitive deterioration resulting from an atrophy of a single 
brain hemisphere. Rasmussen’s encephalitis is divided into two clinical subtypes by the 
existence of epilepsia partialis continua (EPC). EPC is characterized by continuous 
myoclonic jerks of the extremities and/or the face, usually without impairment of 
consciousness (Takahashi et al 1997). The etiology of the disease has been hypothesized to 
be associated with an autoimmune process mediated through antibodies against the 
glutamate receptor subunit 3, (Mastrangelo et al 2010). Takahashi et al. reported that 
antibodies against NMDA type GluRε2 were detected in Rasmussen’s encephalitis patients 
with and without EPC (Pleasure 2008; Takahashi et al 2003; Takahashi et al 2005). This 
suggests that autoantibodies against GluRε2 are important for the diagnosis of both 
subtypes of Rasmussen’s encephalitis, independent of EPC.  
4. Conclusion 
Viral and autoimmune disorders of the CNS are a heterogeneous group of disorders. Many 
viruses are known to cause acute viral encephalitis in humans which can cause a variable 
degree of meningeal as well as parenchymal inflammation. CSF abnormalities typically 
consists lymphocytic pleocytosis and protein elevation. Identification of viral antigens, viral 
nucleic acid or antibody analysis may provide an important diagnostic help in addition to 
imaging (e.g. CT scan and MRI) (Debiasi & Tyler 2004). The clinical and laboratory findings 
in many of those viral and autoimmune disorders are largely similar and thus more specific 
biomarkers for diagnostic and prognostic purposes are warranted. These biomarkers are 
increasingly important in the recognition and treatment of viral and autoimmune CNS 
disorders (Dale & Brilot 2010). 
Many of the viral encephalitides are accompanied by CSF markers for immune activation 
like ┚2 microglobulin and neopterin or elevated levels of cytokines and chemokines in 
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addition to the presence of the virus or viral antigens. Many studies also tried to predict the 
progression of the disease and response to therapeutics base on those biomarkers. Despite 
the plethora of surrogate markers of immune activation and neuronal and glial destruction, 
their clinical use is still obscure in that there are no clinical trials that showed a correlation 
with clinical status and that they respond to a therapeutic intervention. There is a great need 
for validation of these studies in larger trials before surrogate marker measurements would 
be accepted universally as clinical end-points. In conclusion, although more and more 
studies were aimed to identify specific biomarkers for each type of encephalitis there is still 
need for more studies to validate their use in larger trials.  
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